- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03296098
Study of the Safety and Efficacy of Ulipristal Acetate (UPA) Used Daily as a Contraceptive (CCN013B)
A Multi-center, Open-label, Non-comparative Study of the Safety and Contraceptive Efficacy of Continuous Daily Oral 10 mg of Ulipristal Acetate (UPA)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90010
- Essential Access
-
Sacramento, California, United States, 95817
- University of California, Davis
-
San Francisco, California, United States, 94110
- University of California, San Francisco
-
-
Colorado
-
Denver, Colorado, United States, 80045
- University of Colorado
-
-
Hawaii
-
Honolulu, Hawaii, United States, 96826
- University of Hawaii
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- University of Chicago
-
-
Maryland
-
Baltimore, Maryland, United States, 21224
- Johns Hopkins Bayview Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Planned Parenthood League of Massachusetts
-
-
New York
-
New York, New York, United States, 10032
- Columbia University
-
New York, New York, United States, 10016
- New York University, School of Medicine
-
-
Ohio
-
Cincinnati, Ohio, United States, 45267
- University of Cincinnati
-
Cleveland, Ohio, United States, 44106
- University Hospitals of Cleveland MacDonald Women's Hospital
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health & Science University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania Medical Center
-
Pittsburgh, Pennsylvania, United States, 15213
- Univeristy of Pittsburgh School of Medicine
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02905
- Women & Infants Hospital of Rhode Island
-
-
Utah
-
Salt Lake City, Utah, United States, 84106
- University of Utah
-
-
Virginia
-
Norfolk, Virginia, United States, 23507
- Eastern Virginia Medical School (EVMS)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
To enroll into the clinical trial, potential subjects must:
- Be in good general overall health with no chronic medical conditions that result in periodic exacerbations that require significant medical care.
- Be women between 18 and 35 years inclusive at the enrollment visit.
Have regular menstrual cycles that occur every 21-35 days when not using hormonal contraception.
a. If subject is postpartum or post-abortal, she must have one menstrual bleed prior to enrollment.
- Be seeking contraception, and willing to use the study drug as the only contraception method during their months of study participation.
- If using a ring, patch, pill, or implant prior to study treatment, the subject must discontinue the active hormone at least 4 days, and no more than 7 days, prior to study drug initiation. Note that for combined oral contraceptive users, placebo pills are not counted as active hormone.
- If using a hormonal intrauterine device (IUD) prior to study treatment, the IUD must be removed prior to study drug initiation; removal and study drug initiation can occur on the same day, but the subject must refrain from sexual intercourse for 7 days following IUD removal.
- If using a copper IUD prior to study treatment, the IUD must be removed prior to study drug initiation; removal and study drug initiation can occur on the same day. The IUD removal and study drug initiation must occur during the first 7 days of a spontaneous menses.
- If using a non-hormonal contraceptive method (e.g. condoms or withdrawal) prior to study treatment, drug initiation should occur within the first 7 days of a spontaneous menses.
- If the woman has received a long-acting injectable contraceptive (e.g. depomedroxyprogesterone acetate) during the 10 months prior to screening, she must have resumed cyclic spontaneous menses (two menstrual bleeds) since last injection.
- Have a negative urine pregnancy test at the enrollment visit.
- Have an intact uterus and both ovaries.
- In the opinion of the investigator, be willing and able to follow all study requirements, including use of the study product and be willing to record requested information on a daily diary.
- Understand and sign an (Institutional Review Board) IRB approved informed consent form prior to screening activities (including fasting blood draws).
- Have a diastolic blood pressure (BP) ≤95 mm Hg and systolic BP ≤145 mm Hg after 5 minutes in a sitting position at the enrollment visit. Hypertensive subjects who are treatment controlled and, in the judgment of the investigator, are good candidates require a waiver for participation.
- Have a body mass index (BMI) < 40 kg/m2.
- Be planning to have at least one act of heterosexual vaginal intercourse each month during study participation.
- Be willing to accept an unknown risk of pregnancy during study participation.
Exclusion Criteria:
To enroll into the clinical trial, potential subjects must not:
- Be women with irregular menstrual cycles defined as a variation in cycle length of more than 5 days.
- Be planning pregnancy within their months of study participation.
- Be currently breast-feeding or within 30 days of discontinuing breast feeding, unless the subject has already had a menses following discontinuation of breast feeding.
- Have undiagnosed abnormal genital bleeding.
- Have known hypersensitivity to the active substance UPA or any of the excipients of the study treatment.
- Have a history of endometrial hyperplasia or malignancy.
- Have abnormal Transvaginal Ultrasound (TVUS) or safety labs done at the screening visit recognized as clinically significant by the investigator (or medically qualified designee).
- Have a previous history of endometrial ablation.
- Have a previous history of liver disease or screening liver enzyme results more than three times the upper limit of normal values.
- Have a known clinically significant Pap test abnormality, as managed by current local or national guidelines, that would require treatment during study participation.
Have any of the following known contraindication to progestin-only oral contraceptive (OC):
- History or existing breast cancer, or other hormone sensitive neoplasia;
- Current or history of ischemic heart disease or stroke while pregnant or taking birth control pills;
- Systemic Lupus Erythematosus with positive or unknown antiphospholipid antibodies;
- Benign or malignant liver tumors;
- Severe (decompensated) cirrhosis.
- Have known or suspected alcoholism or drug abuse.
- Have known HIV infection.
- Have an anticipated need for regular condom use as defined as use of at least one condom per month after enrollment.
- Have previously participated in the study.
- Have a current need for exogenous hormones or therapeutic anticoagulants.
- Have a current or history of deep vein thromboembolic disorder or aortic thromboembolism, including stroke and myocardial infarction
- Have a current or past medically diagnosed severe depression, which, in the opinion of the investigator, could be exacerbated by use of a hormonal contraceptive, unless she is stable on antidepressant medication.
- Have concomitant use of medication thought to interact with UPA (per Summary of Product Characteristics (SPCs)) such as CYP3A4 inducers (rifampin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, phenytoin, St John's Wort, topiramate).
- Have concomitant use of moderate or strong CYP3A4 inhibitors as identified by the FDA. Subjects who begin use of a moderate CYP3A4 inhibitor after study enrollment require a waiver to continue in the study.
- Use any medications that can interfere with the metabolism of hormonal contraceptives, antibiotics that can interfere with metabolism of hormonal contraceptives, or any drugs designated by the FDA as falling in the Pregnancy and Lactation narrative subsections (formerly Category D or X medications).
- Currently participate in any other trial of an investigational medicine or device or have participated in the three months before start of treatment or be planning to participate in another clinical trial during this study.
- Have a history of a bariatric surgery procedure associated with malabsorption.
- Be planning to undergo major surgery during study participation.
- Live outside of the catchment area of the study site.
- Have used UPA, including Ella, within 30 days prior to enrollment and not had a menses since using UPA.
- Any site staff member with delegated study responsibilities or a family member of a site staff member with delegated study responsibilities.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: ulipristal acetate
Subjects will be administered ulipristal acetate in 5 mg dosages and instructed to take two pills once daily for 6 months.
|
Ulipristal aceteate 5 mg oral tablets to take two tablets daily.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Evaluate the contraceptive efficacy at 6 months based on the calculated Pearl Index for the evaluable for pregnancy population.
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of treatment emergent adverse events (safety and tolerability) during 6 month use of UPA.
Time Frame: 6 months
|
6 months
|
Changes from baseline in sodium levels (safety and tolerability).
Time Frame: 6 months
|
6 months
|
Changes from baseline in potassium levels (safety and tolerability).
Time Frame: 6 months
|
6 months
|
Changes from baseline in chloride levels (safety and tolerability).
Time Frame: 6 months
|
6 months
|
Changes from baseline in bicarbonate levels (safety and tolerability).
Time Frame: 6 months
|
6 months
|
Changes from baseline in fasting glucose levels (safety and tolerability).
Time Frame: 6 months
|
6 months
|
Changes from baseline in blood urea nitrogen levels (safety and tolerability).
Time Frame: 6 months
|
6 months
|
Changes from baseline in creatinine levels (safety and tolerability).
Time Frame: 6 months
|
6 months
|
Changes from baseline in calcium levels (safety and tolerability).
Time Frame: 6 months
|
6 months
|
Changes from baseline in total bilirubin levels (safety and tolerability).
Time Frame: 6 months
|
6 months
|
Changes from baseline in total alkaline phosphatase levels (safety and tolerability).
Time Frame: 6 months
|
6 months
|
Changes from baseline in total alanine aminotransferase levels (safety and tolerability).
Time Frame: 6 months
|
6 months
|
Changes from baseline in total aspartate transaminase levels (safety and tolerability).
Time Frame: 6 months
|
6 months
|
Changes from baseline in total albumin levels (safety and tolerability).
Time Frame: 6 months
|
6 months
|
Changes from baseline in total cholesterol levels (safety and tolerability).
Time Frame: 6 months
|
6 months
|
Changes from baseline in HDL cholesterol levels (safety and tolerability).
Time Frame: 6 months
|
6 months
|
Changes from baseline in LDL cholesterol levels (safety and tolerability).
Time Frame: 6 months
|
6 months
|
Changes from baseline in triglycerides levels (safety and tolerability).
Time Frame: 10 months
|
10 months
|
Changes from baseline in acceptability of UPA using an Acceptability Questionnaire (acceptability).
Time Frame: 6 months
|
6 months
|
Changes from baseline in bleeding pattern using a subject diary (tolerability).
Time Frame: 6 months
|
6 months
|
Changes from baseline in endometrial thickness using transvaginal ultrasound.
Time Frame: 6 months
|
6 months
|
Changes from baseline in endometrium using endometrial biopsy results.
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CCN013B
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Contraception
-
Virginia Commonwealth UniversityCompletedPregnancy Related | Contraception | Contraception Behavior | Contraception Use
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedFemale Contraception | Contraception
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedFemale Contraception | Contraception
-
Janssen Pharmaceutica N.V., BelgiumCompleted
-
Medical University of South CarolinaSociety of Family PlanningCompletedContraception | Contraception BehaviorUnited States
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedFemale Contraception | ContraceptionUnited States, Israel
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedFemale Contraception | Contraception
-
University of California, San FranciscoAgency for Healthcare Research and Quality (AHRQ); Essential Access HealthNot yet recruitingContraception | Contraception Behavior | Reproductive BehaviorUnited States
Clinical Trials on Ulipristal acetate
-
Northwestern UniversityUnknown
-
PregLem SACompletedUterine FibroidsUnited Kingdom, Belgium, Czechia, France, Germany, Hungary, Italy, Latvia, Lithuania, Romania, Ukraine
-
Eunice Kennedy Shriver National Institute of Child...HRA PharmaCompletedLeiomyomaUnited States
-
Population CouncilUnknown
-
Stanford UniversityCompleted
-
Northwestern UniversitySociety of Family PlanningRecruitingContraception | Contraceptive Usage | Reproductive IssuesUnited States
-
Instituto Valenciano de Infertilidad, IVI VALENCIATerminated
-
Manchester University NHS Foundation TrustUniversity of ManchesterCompleted
-
Fundació Institut de Recerca de l'Hospital de la...UnknownTreatment Side Effects | Leiomyoma, Uterine | Liver InjurySpain
-
Mỹ Đức HospitalTerminatedUterine Fibroid | Heavy Menstrual BleedingVietnam